HC Wainwright Reaffirms "Buy" Rating for Mural Oncology (NASDAQ:MURA)

Mural Oncology (NASDAQ:MURA - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 397.24% from the company's previous close.

Separately, Raymond James assumed coverage on Mural Oncology in a report on Friday, October 4th. They set a "strong-buy" rating and a $18.00 target price for the company.

Mural Oncology Stock Performance

MURA traded up $0.10 during trading on Monday, hitting $3.62. 53,057 shares of the stock were exchanged, compared to its average volume of 179,776. The firm has a 50 day simple moving average of $3.36 and a 200 day simple moving average of $3.38. The firm has a market cap of $61.68 million and a price-to-earnings ratio of -0.34. Mural Oncology has a 1 year low of $2.88 and a 1 year high of $17.00.

Mural Oncology (NASDAQ:MURA - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.90) by $0.04. As a group, equities analysts anticipate that Mural Oncology will post -7.59 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Adam D. Cutler sold 7,421 shares of the firm's stock in a transaction that occurred on Thursday, October 31st. The shares were sold at an average price of $3.41, for a total transaction of $25,305.61. Following the completion of the transaction, the chief financial officer now directly owns 71,438 shares of the company's stock, valued at $243,603.58. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company's stock.

Hedge Funds Weigh In On Mural Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the business. BBR Partners LLC acquired a new stake in Mural Oncology during the 2nd quarter worth about $31,000. Rhumbline Advisers purchased a new position in Mural Oncology in the second quarter valued at about $34,000. Commerce Bank acquired a new position in Mural Oncology in the third quarter worth approximately $39,000. Canada Pension Plan Investment Board acquired a new position in Mural Oncology during the second quarter worth $70,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Mural Oncology during the 2nd quarter worth about $71,000. 80.21% of the stock is currently owned by hedge funds and other institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.